Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

This retrospective analysis (n=535) describes the access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD). Of the pharmacy claims for esketamine, 34.6% were approved, 46.3% were rejected, and 19.1% were abandoned. The approval rate increased to 85.2% by the second treatment session. Among 273 patients who initiated esketamine (mean age 49.3 years; 66.3% female), the mean number of sessions was 11.8 over a mean of 11.8 months, with 47.6% completing at least eight sessions, and 93.8% of those completing induction continuing treatment.

Abstract of Access & real-world use patterns of esketamine among patients with depression (TRD) covered by insurance

“Objective: To describe access and real-world use patterns of esketamine nasal spray among adults with treatment-resistant depression (TRD) with private or public insurance.

Methods: Adults with ≥1 claim for esketamine nasal spray were selected from Clarivate’s Real World Data product (01/2016-03/2021). Patients with evidence of TRD initiating esketamine (index date) after 03/05/2019 were included. Esketamine access, as measured by pharmacy claim approval rate for each treatment session, and use patterns were described post-index (follow-up period).

Results: Among 535 patients with pharmacy claims for esketamine nasal spray (mean age 49.1 years; 65.4% female), 534 had the first esketamine claim being a pharmacy claim, of which 34.6% were approved, 46.3% were rejected, and 19.1% were abandoned. Main reasons for rejection included “claim not covered by plan” (57.1%), “claim errors” (52.6%), and “prior authorization required” (22.7%). The approval rate increased to 85.2% by the second esketamine treatment session. A total of 273 patients initiated esketamine (mean age 49.3 years; 66.3% female). Patients had a mean ± standard deviation (SD) of 11.8 ± 13.3 esketamine sessions over a mean ± SD of 11.8 ± 6.4 months; 47.6% of patients completed ≥8 sessions (i.e., the number of sessions in induction phase) over a mean ± SD of 80.1 ± 71.9 days (per label, 28 days); 48 (17.6%) patients completed induction per label, and among them 93.8% continued treatment.

Conclusions: Initial access to esketamine nasal spray may be hindered by prior authorization or claim filing errors. Among patients who initiated esketamine, treatment compliance generally deviates from label recommendations; yet, most of those who received induction per label successfully transition to maintenance with esketamine.”

Authors: Amanda Teeple, Maryia Zhdanava, Dominic Pilon, Gabrielle Caron-Lapointe, Patrick Lefebvre & Kruti Joshi

Summary of Access & real-world use patterns of esketamine among patients with depression (TRD) covered by insurance

Major depressive disorder (MDD) is a chronic psychiatric condition annually affecting 8.4% of adults in the United States. Approximately 30% of patients with MDD experience treatment-resistant depression.

Esketamine is a novel nasal spray approved for treatment of TRD in adults in the US. It reduces depressive symptoms in as early as 24 h after the first dose.

Access to esketamine through health insurance in the US is often subject to prior authorization, which requires a patient to demonstrate true medical needs for the medication and to have tried cost-effective alternatives before receiving more expensive therapies.

To access this content, you must purchase one of the following memberships: Sprout Membership, Pro Membership, Pro Membership Unlimited, Business Membership or Business Membership Unlimited. The membership will give you access to exclusive data, including summaries of psychedelic research papers, extended company info, and our member-only visualisations. Save yourself multiple hours each week by accessing Blossom’s resource library.

Find this paper

Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance

https://doi.org/10.1080/03007995.2023.2239045

Paywall | Google Scholar | Backup | 🕊

Cite this paper (APA)

Teeple, A., Zhdanava, M., Pilon, D., Caron-Lapointe, G., Lefebvre, P., & Joshi, K. (2023). Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance. Current Medical Research and Opinion, (just-accepted), 1-12.

Study details

Compounds studied
Ketamine

Topics studied
Economics Treatment-Resistant Depression Depression

Study characteristics
Survey

Participants
535 Humans

Linked Research Papers

Notable research papers that build on or are influenced by this paper

Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States
This real-world (n=269) analysis of esketamine (Spravato) use finds nearly 50% of patients had their first pharmacy claim approved. Of those approved, 45% had eight or more treatment sessions (as recommended), though spread over 85 days (versus 28 per the label). Patients had lower health utilization, but this could be due to factors outside of the esketamine treatment (e.g. regression to the mean).